Floatz Rating
BB65/100
Confidence
Indicative
Sponsor
Fusion Pharmaceuticals Inc.
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
65High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06909825CT.gov FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) | — | Active Not Recruiting | — | — | — |
NCT05700669CT.gov Study to Assess Safety and Efficacy of AsiDNA in Combination with Olaparib in Participants with Recurrent Solid Tumors | — | Completed | — | — | — |
NCT05457257CT.gov Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations | — | Active Not Recruiting | — | — | — |
NCT05167175CT.gov The Study of Olaparib Combined With Abiraterone and Prednisone in mHSPC Patients With HRR Gene Mutation | — | Unknown | — | — | — |
NCT05262608CT.gov The Study of Olaparib in Newly Diagnosed mCRPC Patients With HRR Gene Mutation | — | Unknown | — | — | — |
NCT05005728CT.gov XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer | — | Completed | — | — | — |
NCT05171816CT.gov Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort) | — | Active Not Recruiting | — | — | — |
NCT04556617CT.gov PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) | — | Terminated | — | — | — |
NCT03682289CT.gov Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT03732820CT.gov Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer | — | Active Not Recruiting | — | — | — |
Show 7 more trialsShow fewer
NCT03568656CT.gov Study to Evaluate CCS1477 in Advanced Tumours | — | Completed | — | — | — |
NCT03434158CT.gov Olaparib Maintenance in Patients With MCRPC After Docetaxel Treatment Reaching Partial or Stable Response (IMANOL) | — | Completed | — | — | — |
NCT02893917CT.gov Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer | — | Active Not Recruiting | — | — | — |
NCT02987543CT.gov Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study) | — | Completed | — | — | — |
NCT03012321CT.gov Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects | — | Active Not Recruiting | — | — | — |
NCT02861573CT.gov Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365) | — | Recruiting | — | — | — |
NCT01972217CT.gov Ph II Study to Evaluate Olaparib With Abiraterone in Treating Metastatic Castration Resistant Prostate Cancer. | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Metastatic Prostate Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Olaparib (this asset) | Fusion Pharmaceuticals Inc. | Approved | BB · 65 |
| AXUMIN | VA Greater Los Angeles Healthcare System | P4 | BBB |
| Leuporelin | Mayo Clinic | P4 | BBB |
| Abiraterone | Mayo Clinic | P4 | BB |
| Prednisone | Mayo Clinic | P4 | BB |
| Pembrolizumab | CuraCell TX AB | P2 | BB |
| Degarelix | Praful Ravi, MB BCHir, MRCP | P3 | BB |
| Cabazitaxel | AstraZeneca | P4 | BB |
| Sipuleucel-T | Yale University | P2 | BB |
+42 more in the Metastatic Prostate Carcinoma cohort
Other indications for Olaparib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Breast Carcinoma | — | P4 | BBB · 73 |
| Fallopian Tube Serous Adenocarcinoma | — | P3 | BBB · 72 |
| Ovarian Carcinoma | — | P4 | BB · 71 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Olaparib in Metastatic Prostate Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/olaparib-metastatic-prostate-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →